Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Gaucher Step Therapy Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentZing HealthPolicy 4219-D

    Medicare Part B Step Therapy Gaucher Disease Agents

    Customize your policy alerts

    Sign up for zing_health Policy 4219-D alerts

    Get alerted when Policy 4219-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage of specified Gaucher disease products under Zing Health's Advanced Biosimilars First step-therapy program. It establishes preferred products and an exception process requiring prior authorization for nonpreferred products, primarily for members new to nonpreferred treatment.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Gaucher Disease Agents
    Policy CodePolicy 4219-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Cerezyme or Elelyso before requesting nonpreferred VPRIV, unless an approved exception applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred Gaucher disease products
    1Nonpreferred Gaucher disease product
    3Exception pathways
    365 daysPrior-treatment lookback

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Nonpreferred Product Exception Criteria

    Nonpreferred product exception criteria

    Coverage for a nonpreferred product is provided when ANY of the following criteria is met.

    Nonpreferred product exception

    • Recent prior use: Member has received treatment with the nonpreferred product in the past 365 dayswithin the past 365 days
    • Cerezyme exception for age 2 to 4: Member has had a documented inadequate response or an intolerable adverse event with Cerezyme and is between 2 and 4 years of ageage 2 through 4 years

      Both inadequate response or intolerable adverse event with Cerezyme and the specified age range are required

    • Failure or intolerance of both preferred products: Member has had a documented inadequate response or an intolerable adverse event with both Cerezyme and Elelysoboth preferred products

      Inadequate response or intolerable adverse event must be documented for each preferred product

    Initial Nonpreferred Product Therapy

    Initial nonpreferred product therapy

    For a member requesting a nonpreferred product for an FDA-approved indication of the preferred product, coverage is provided when ANY of the following criteria is met.

    Initial nonpreferred therapy exception

    • Prior nonpreferred treatment: Member has received treatment with the nonpreferred product in the past 365 dayswithin the past 365 days
    • Cerezyme inadequate response or intolerance with age requirement: Member has had a documented inadequate response or an intolerable adverse event with Cerezyme and is between 2 and 4 years of ageage 2 through 4 years

      Both components are required

    • Both preferred products inadequate or intolerable: Member has had a documented inadequate response or an intolerable adverse event with both Cerezyme and Elelysoboth preferred products

      Both preferred products must be documented as ineffective or intolerable

    Preferred and Nonpreferred Products

    ProductPlan statusRequirement
    Cerezyme (imiglucerase)PreferredUse before requesting VPRIV, unless an approved exception applies.
    Elelyso (taliglucerase alfa)PreferredUse before requesting VPRIV, unless an approved exception applies.
    VPRIV (velaglucerase alfa)Non-preferred; exception requiredRequires an exception through prior authorization. Coverage may be provided when the member received VPRIV within the past 365 days, had an inadequate response or intolerable adverse event with Cerezyme and is 2 through 4 years of age, or had an inadequate response or intolerable adverse event with both Cerezyme and Elelyso.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Review

    Submit a clinical prior authorization request for a nonpreferred product, including the applicable exception rationale and supporting documentation. Preferred products may also require a clinical prior authorization review.

    • Nonpreferred product requests are subject to exception review through prior authorization.
    • Apply any applicable Medicare Part B National Coverage Determination (NCD), Local Coverage Determination (LCD), and client Medicare Part B utilization management (UM) requirements.
    Step Therapy

    Program Applicability

    Apply step therapy to members who are new to treatment with a nonpreferred Gaucher disease product for the first time. Coverage for a nonpreferred product depends on clinical circumstances that exclude use of a preferred product and may be based on prior product use.

    • The program applies to the Gaucher disease products specified in this policy.
    • The coverage review process determines whether a clinical exception can be granted.
    Step Therapy

    Preferred Product Step Required

    Use a preferred product before requesting nonpreferred VPRIV, unless a documented clinical exception applies. The preferred products are Cerezyme (imiglucerase) and Elelyso (taliglucerase alfa).

    • Preferred: Cerezyme (imiglucerase).
    • Preferred: Elelyso (taliglucerase alfa).
    • Nonpreferred: VPRIV (velaglucerase alfa).
    • This program applies when the requested indication is FDA-approved for the preferred product.
    Documentation Required

    Clinical Exception Documentation

    Document the clinical basis for a nonpreferred product exception. Supporting records must establish the applicable prior treatment, inadequate response, or intolerance criteria.

    • Document treatment with the nonpreferred product within the past 365 days, if applicable.
    • Document an inadequate response or intolerable adverse event with Cerezyme in a member 2 through 4 years of age, if applicable.
    • Document an inadequate response or intolerable adverse event with both preferred products: Cerezyme and Elelyso, if applicable.
    Denial Risk

    Exception Criteria Not Met

    A nonpreferred product request may be denied when the requested indication is not FDA-approved for the preferred product or when the requirements for a clinical exception are not met. Coverage is available only when at least one approved exception criterion is documented.

    • The member received the nonpreferred product within the past 365 days.
    • The member is 2 through 4 years of age and has a documented inadequate response or intolerable adverse event with Cerezyme.
    • The member has a documented inadequate response or intolerable adverse event with both Cerezyme and Elelyso.
    • Requests that do not satisfy at least one exception criterion may be denied.

    Policy Scope

    This policy addresses Medicare Part B Gaucher disease products under Zing Health’s Advanced Biosimilars First step-therapy program. Cerezyme (imiglucerase) and Elelyso (taliglucerase alfa) are the preferred products, while VPRIV (velaglucerase alfa) is nonpreferred. The program applies to members who are new to nonpreferred treatment and provides an exception process through prior authorization when clinical circumstances support use of the nonpreferred product.

    Step therapy applies to treatment for an indication that is FDA-approved for the preferred product. Review is conducted in addition to any applicable Medicare Part B National Coverage Determination (NCD), Local Coverage Determination (LCD), or client-implemented utilization management program.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Gaucher Disease Agents
    Policy CodePolicy 4219-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Cerezyme or Elelyso before requesting nonpreferred VPRIV, unless an approved exception applies.
    SourceLink
    On This Page
    Nonpreferred Product Exception CriteriaInitial Nonpreferred Product TherapyPreferred and Nonpreferred ProductsAuthorization and Documentation RequirementsPolicy Scope